Abstract:ID 131403 Poster Board 569 Chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are highly homologous G-protein coupled receptors on the surface of select immune cells with distinct functions and endogenous agonists but with select shared antagonists. These chemokine receptors are promising targets for small molecule therapeutics in the treatment of various cancers and autoimmune diseases, despite only one currently approved therapeutic for CCR5. Rational design of future therapeutics relies on a structural understanding of the determinants of antagonist selectivity as high affinity targeting of only one receptor is often desired. Further complicating therapeutic development, antagonists of human CCR2 (hCCR2) are often inactive to mouse CCR2 (mCCR2). Here, through rationally-guided gain-of-function mutagenesis, we characterized the molecular determinants of CCR2/CCR5 and human/mouse antagonist selectivity. Binding poses for a panel of selective and dual-specific antagonists were generated through molecular docking. Using these poses, we hypothesized that a single bulky residue in TM2 of hCCR5 (Y892.63) and mCCR2 (Y1142.63) dictates selectivity by obstructing binding of the minor pocket-targeting orthosteric antagonists with large substituents. By contrast, the corresponding S1012.63 of hCCR2 is permissive to the binding of such antagonists because it allows them to occupy space otherwise filled by tyrosine. To validate this hypothesis, we introduced a Y892.63S mutation into human CCR5 and tested the ability of a previously CCR2-selective antagonist cherney08a_22 to inhibit chemokine-induced suppression of forskolin-stimulated cAMP in HeLa cells expressing the mutant. Intracellular cAMP levels were measured with the BRET-based CAMYEL reporter. These experiments confirmed that indeed the CCR5(Y892.63S) mutant became sensitive to cherney08a_22 . We also demonstrated how the same residue could impart selectivity against human CCR5 and mouse CCR2 to antagonists with a medium-size (acetamide) substituent. An alternative hypothesis was assessed for CCR2-selective antagonists predicted to bind towards TM5 and the major pocket. Selectivity for these hCCR2 antagonists was suspected to be conveyed by residues F1093.33, S18045.52, or I1985.42 of human CCR5, which are distinct from their CCR2 counterparts. However, the introduction of CCR2-mimicking F1093.33H and S18045.52P mutations in hCCR5 was not sufficient to produce sensitivity to major pocket-targeting CCR2-selective antagonist PF-4136309 . We therefore concluded that its selectivity mechanism is due to the hCCR2 residue R2065.42 which is I1985.42 in hCCR5. Our findings provide a better framework for the rational development of selective and dual-affinity antagonists for CCR2 and CCR5 to overcome past deficiencies in design of potent and selective inhibitors.

SR16951, a new small molecule antagonist of MCP-1 for the treatment of autoimmune diseases (50.13)

Small Molecule Inhibits Activity of Scavenger Receptor A: Lead Identification and Preliminary Studies

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects

Understanding Molecular Interactions Between Scavenger Receptor A and Its Natural Product Inhibitors Through Molecular Modeling Studies.

Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases

ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A

P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBD

Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.

SR-A Neutralizing Antibody: Potential Drug Candidate for Ameliorating Osteoclastogenesis in Rheumatoid Arthritis

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

Novel Anti-Inflammatory Peptides Based on Chemokine-Glycosaminoglycan Interactions Reduce Leukocyte Migration and Disease Severity in a Model of Rheumatoid Arthritis

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk